Superseded · version 1: Amycretin^↗

An amylin and GLP-1 receptor agonist candidate represented in ClinicalTrials.gov.^↗

This is preserved historical wording.
It is no longer the current profile. Read the current profile and its correction notice.

What this version reported

ClinicalTrials.gov lists a Novo Nordisk oral amycretin study as completed, last updated March 5, 2025.^↗

Organizations named in cited records:

Trial records: NCT06049329